Sangamo Therapeutics Sells Key Assets for Up to $100M Amidst Chapter 11 Bankruptcy

summarizeSummary

Sangamo Therapeutics has finalized agreements to sell its gene therapy platforms and Fabry disease program for up to $100 million, providing crucial capital during its Chapter 11 bankruptcy.

check_boxKey Events

• Asset Sale to Eli Lilly

  Sangamo is selling its proprietary capsids (STAC-150, STAC-BBB), SIFTER, MINT, and zinc finger platforms, along with its prion program, to Merope Acquisition Sub, LLC (a subsidiary of Eli Lilly and Company) for $50 million.

• Fabry Program Sale to Astellas

  The company is selling its Fabry disease gene therapy product (ST-920) to Astellas Gene Therapies for $25 million upfront, with potential for an additional $25 million in milestone payments.

• Bankruptcy Context

  These asset sales are being conducted under Chapter 11 bankruptcy proceedings, with both agreements dated June 22, 2026, one day before the expected bankruptcy filing.

• Break-Up Fees

  The Eli Lilly agreement includes a $1.5 million break-up fee and up to $500,000 in expense reimbursement, while the Astellas agreement includes a $1 million termination fee and up to $500,000 in expense reimbursement.

auto_awesomeAnalysis

This amended 8-K provides critical details of asset purchase agreements entered into by Sangamo Therapeutics as part of its Chapter 11 bankruptcy proceedings. The company is selling its proprietary capsid and gene therapy platforms to Eli Lilly for $50 million, and its Fabry disease gene therapy program (ST-920) to Astellas Gene Therapies for $25 million upfront plus up to $25 million in milestones. These sales, totaling up to $100 million, are a direct consequence of the company's severe financial distress and recent bankruptcy filing, representing a significant divestiture of its core R&D assets.